Groowe Groowe / Newsroom / GTBP
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GTBP News

GT Biopharma Inc. Common Stock

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

globenewswire.com
GTBP

The $13 Million Company Teaching the Immune System to Hunt Cancer

prnewswire.com
NKTX GTBP IBRX FATE ARTV

Form 8-K

sec.gov
GTBP

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

prnewswire.com
NKTX GTBP IBRX FATE INMB

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

prnewswire.com
IPHA GTBP GSK SMMT IDYA

GT Biopharma Reports First Quarter 2026 Financial Results

globenewswire.com
GTBP

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

globenewswire.com
GTBP VIR ONCY SNSE

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

globenewswire.com
GTBP SMMT IDYA RADX

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

prnewswire.com
GTBP ARTV FATE IBRX CHRS

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

globenewswire.com
GTBP